These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
101 related articles for article (PubMed ID: 16463546)
1. [New targets for cancer treatment]. Heinzl S Med Monatsschr Pharm; 2006 Jan; 29(1):1. PubMed ID: 16463546 [No Abstract] [Full Text] [Related]
2. Molecular basis of the anti-cancer effects of histone deacetylase inhibitors. Epping MT; Bernards R Int J Biochem Cell Biol; 2009 Jan; 41(1):16-20. PubMed ID: 18765293 [TBL] [Abstract][Full Text] [Related]
3. Histone deacetylase inhibitors in cancer therapy. Fouladi M Cancer Invest; 2006; 24(5):521-7. PubMed ID: 16939962 [No Abstract] [Full Text] [Related]
4. Development of histone deacetylase inhibitors for cancer treatment. Marchion D; Münster P Expert Rev Anticancer Ther; 2007 Apr; 7(4):583-98. PubMed ID: 17428177 [TBL] [Abstract][Full Text] [Related]
5. Histone deacetylase inhibitors: from bench to clinic. Paris M; Porcelloni M; Binaschi M; Fattori D J Med Chem; 2008 Mar; 51(6):1505-29. PubMed ID: 18247554 [No Abstract] [Full Text] [Related]
6. [[Inhibitors of histone deacetylase as new agents for prevention and treatment of cancer] ]. Jung M Pharm Unserer Zeit; 2000 Nov; 29(6):385-8. PubMed ID: 11199916 [No Abstract] [Full Text] [Related]
7. Histone deacetylase inhibitors: overview and perspectives. Dokmanovic M; Clarke C; Marks PA Mol Cancer Res; 2007 Oct; 5(10):981-9. PubMed ID: 17951399 [TBL] [Abstract][Full Text] [Related]
12. AACR-NCI-EORTC--19th symposium. Molecular Targets and Cancer Therapeutics--Part 2. Searle B; Collins T IDrugs; 2007 Dec; 10(12):836-9. PubMed ID: 18041674 [No Abstract] [Full Text] [Related]
13. Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors. Prince HM; Bishton MJ; Johnstone RW Future Oncol; 2009 Jun; 5(5):601-12. PubMed ID: 19519200 [TBL] [Abstract][Full Text] [Related]
14. Effect of the histone deacetylase inhibitor trichostatin a in human peripheral blood lymphocytes as a function of donor age. Sourlingas TG; Kypreou KP; Topakas GN; Karchilaki IN; Stavropoulos-Giokas C; Sekeri-Pataryas KE Ann N Y Acad Sci; 2007 Nov; 1119():64-71. PubMed ID: 18056955 [TBL] [Abstract][Full Text] [Related]
16. Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy. Carew JS; Giles FJ; Nawrocki ST Cancer Lett; 2008 Sep; 269(1):7-17. PubMed ID: 18462867 [TBL] [Abstract][Full Text] [Related]
17. The molecular mechanism of HDAC inhibitors in anticancer effects. Bi G; Jiang G Cell Mol Immunol; 2006 Aug; 3(4):285-90. PubMed ID: 16978537 [TBL] [Abstract][Full Text] [Related]
18. Histone deacetylase inhibitors and demethylating agents: clinical development of histone deacetylase inhibitors for cancer therapy. Piekarz RL; Sackett DL; Bates SE Cancer J; 2007; 13(1):30-9. PubMed ID: 17464244 [TBL] [Abstract][Full Text] [Related]
19. Histone deacetylase inhibitors: molecular mechanisms of action. Xu WS; Parmigiani RB; Marks PA Oncogene; 2007 Aug; 26(37):5541-52. PubMed ID: 17694093 [TBL] [Abstract][Full Text] [Related]
20. HDAC inhibitors: a potential new category of anti-tumor agents. Pan LN; Lu J; Huang B Cell Mol Immunol; 2007 Oct; 4(5):337-43. PubMed ID: 17976313 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]